Question:

Mentioned on Google. I’ll be getting another DEXA scan in a few months, and my Physician has mentioned that something might be needed now that I am off the estrogen. Comments?

Response:

"Amethyst" <adoptsoldc…@aol.com> wrote in message

news:[email protected]… > Mentioned on Google. I’ll be getting another DEXA scan in a few months, > and my Physician has mentioned that something might be needed now that > I am off the estrogen. Comments?

Nope, not yet.  I *just* heard it mentioned on the news, on NPR.  No details. Cathy – Hide quoted text — Show quoted text –

Response:

On 25 Mar 2005 11:46:19 -0800, "Amethyst" <adoptsoldc…@aol.com> wrote: >Mentioned on Google. I’ll be getting another DEXA scan in a few months, >and my Physician has mentioned that something might be needed now that >I am off the estrogen. Comments?

Once monthly Boniva: The most commonly reported adverse events with once-monthly Boniva regardless of causality were abdominal pain (Boniva 150 mg 7.8 percent vs. Boniva 2.5 mg 5.3 percent), hypertension (6.3 percent vs. 7.3 percent), dyspepsia (5.6 percent vs. 7.1 percent), arthralgia (5.6 percent vs. 3.5 percent), nausea (5.1 percent vs. 4.8 percent) and diarrhea (5.1 percent vs. 4.1 percent). For the daily version,(which was approved but never launched) http://www.rxlist.com/cgi/generic3/boniva_cp.htm (Clinical pharmacology tab) reveals that the women in the relevant clinical studies for *treatment* of osteoporosis were on average 22 years postmenopausal and that they all already had  1 to 4 vertebral fractures (I.e. had ‘established" osteoporosis. Despite this, whereas there was a reduction in vertebral fractures (in the studies) there was NO reduction (despite increased BMD)at any other fracture sites e.g hip and wrist.  Interestingly, almost half of the new vertebral fractures (whether with drug or with placebo) were not symptomatic and the women were unaware of them. For prevention purposes, the women were younger with BMD better than osteoporotic and again there was an increase in BMD over the 2 years of the study. However no mention is made of fracture rates, which is the real point of treatment and given that increased BMD didn’t help the "treatment" group with nonvertebral fractures it doesn’t sound like anything I’d consider.

Response:

Related Questions